Dollars for Profs

Dig Into University Researchers' Outside Income and Conflicts of Interest

Published Dec. 6, 2019

This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.

Financial doc
Filing Type

Conflict of Interest

Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.

Should you be removed from our database? Contact us at [email protected]. Read more below.

Annabelle Rodiriguez

University of Connecticut Sch of Med/dnt, Department: Biology

Should you be removed from our database? Contact us at [email protected]. Read more below.

Disclosed Conflict of Interest with

Lipids Genomics

Disclosed Value
Listed Reason
Intellectual property rights (e.g., royalties, patents, copyrights) not from the awardee Institution

Dr Rodriguez-Oquendo is the sole owner of Lipids Genomics
She is the inventor of "Plasma Lymphocyte Activation Gene (LAG3) Levels as a Biomarker for Dysfunctional HDL Cholesterol”. Patent applications have been filed covering the assay for LAG3 and also covering methods of treating people who have dysfunctional HDL as indicated by the LAG3 test.
The University owns the patent and licensed the IP exclusively to Lipid Genomics. UConn received (b)(4) fee from Lipid Genomics (partially used to offset the patent cost) No royalties for Dr Rodriguez-Oquendo yet

Listed Research Project
Lympocyte Activation Gene-3 Deficiency Linked to Proinflammation and Atherosclerosis

Heart disease remains a leading cause of death in the United States and throughout the world. We are now better appreciating the role of genetics as a cause for heart disease. Our research work will examine the intersection of genetics, cholesterol, and inflammation in the causes of heart disease. The results of our work will provide customized approaches in the medical treatment of people with certain genetic cholesterol problems and heart disease.

Filed on October 24, 2016.

Tell us what you know about Annabelle Rodiriguez's disclosure

We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?

Name Institution Type Company Disclosed Value
Annabelle Rodiriguez University of Connecticut Sch of Med/dnt Conflict of Interest Lipids Genomics Value cannot be readily determined
If you see an error in the database or a reason we should not disclose a record, please contact us at [email protected] and we'll evaluate it on a case-by-case basis.
Sources: National Institutes of Health, public records requests filed at multiple public state universities

Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.

Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.

ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.

Close Comment Creative Commons Donate Email Facebook Mobile Phone Podcast Print RSS Search Search Twitter WhatsApp
Current site Current page